Viridian Therapeutics, Inc.\DE (VRDN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25M 50M 75M Q3 '16: 6.7M Q4 '16: 5.6M Q1 '17: 4M Q2 '17: 2.6M Q3 '17: 3.3M Q4 '17: 4M Q1 '18: 8.3M Q2 '18: 9.8M Q3 '18: 9.1M Q4 '18: 8.4M Q1 '19: 4M Q2 '19: 4.3M Q3 '19: 4.1M Q4 '19: 4.5M Q1 '20: 4.9M Q2 '20: 2.6M Q3 '20: 1.9M Q4 '20: 1.1M Q1 '21: 1.7M Q2 '21: 2.6M Q3 '21: 2.8M Q4 '21: 3M Q1 '22: 1.7M Q2 '22: 894K Q3 '22: 1.9M Q4 '22: 1.8M Q1 '23: 1.7M Q2 '23: 1.5M Q3 '23: 347K Q4 '23: 314K Q1 '24: 288K Q2 '24: 288K Q3 '24: 302K Q4 '24: 302K Q1 '25: 302K Q2 '25: 305K Q3 '25: 70.8M Q4 '25: 70.8M Q1 '26: 70.9M Q2 '26: 71.1M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 2M 4M 6M Q4 '13: 2.7M Q1 '14: 3M Q2 '14: 3M Q3 '14: 3.3M Q4 '14: 3.1M Q1 '15: 2.9M Q2 '15: 3M Q3 '15: 2.8M Q4 '15: 3.3M Q1 '16: 4.1M Q2 '16: 4.8M Q3 '16: 4.4M Q4 '16: 3.1M Q4 '13 Q2 '14 Q4 '14 Q2 '15 Q4 '15 Q2 '16 Q4 '16

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '16: -14M Q4 '16: -17M Q1 '17: -20.4M Q2 '17: -24.3M Q3 '17: -26.1M Q4 '17: -26.5M Q1 '18: -24.2M Q2 '18: -25.7M Q3 '18: -29M Q4 '18: -33.1M Q1 '19: -40.2M Q2 '19: -40.3M Q3 '19: -42.4M Q4 '19: -42M Q1 '20: -38.2M Q2 '20: -35.7M Q3 '20: -29.9M Q4 '20: -110.4M Q1 '21: -120.9M Q2 '21: -132.5M Q3 '21: -141.2M Q4 '21: -79.7M Q1 '22: -87.1M Q2 '22: -98.7M Q3 '22: -114.3M Q4 '22: -134.3M Q1 '23: -180.9M Q2 '23: -210.6M Q3 '23: -232M Q4 '23: -254.4M Q1 '24: -237.9M Q2 '24: -250.8M Q3 '24: -283M Q4 '24: -299M Q1 '25: -337M Q2 '25: -371.6M Q3 '25: -328.1M Q4 '25: -363.4M Q1 '26: -385.7M Q2 '26: -405.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q3 '16: -14.3M Q4 '16: -17.3M Q1 '17: -20.6M Q2 '17: -24.4M Q3 '17: -26.1M Q4 '17: -26.5M Q1 '18: -24.2M Q2 '18: -25.6M Q3 '18: -28.8M Q4 '18: -32.7M Q1 '19: -39.7M Q2 '19: -39.9M Q3 '19: -42.1M Q4 '19: -41.9M Q1 '20: -38.3M Q2 '20: -35.8M Q3 '20: -30.1M Q4 '20: -110.7M Q1 '21: -121.1M Q2 '21: -132.7M Q3 '21: -141.2M Q4 '21: -79.4M Q1 '22: -86.6M Q2 '22: -98.2M Q3 '22: -113M Q4 '22: -129.9M Q1 '23: -172.3M Q2 '23: -197.9M Q3 '23: -216.7M Q4 '23: -237.7M Q1 '24: -218.1M Q2 '24: -228.1M Q3 '24: -257.1M Q4 '24: -269.9M Q1 '25: -308.3M Q2 '25: -344.1M Q3 '25: -302M Q4 '25: -342.6M Q1 '26: -360.6M Q2 '26: -387M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 1.5M 3M 4.5M Q4 '13: 2.8M Q1 '14: 2.7M Q2 '14: 3.1M Q3 '14: 3.3M Q4 '14: 3.4M Q1 '15: 3.4M Q2 '15: 3.1M Q3 '15: 2.8M Q4 '15: 2.5M Q1 '16: 2.3M Q2 '16: 2.3M Q3 '16: 2.3M Q4 '16: 2.5M Q4 '13 Q2 '14 Q4 '14 Q2 '15 Q4 '15 Q2 '16 Q4 '16

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '16: -12.8M Q4 '16: -14.8M Q1 '17: -18.8M Q2 '17: -21.4M Q3 '17: -24.2M Q4 '17: -28.2M Q1 '18: -27.3M Q2 '18: -24.8M Q3 '18: -25.9M Q4 '18: -26.8M Q1 '19: -31.3M Q2 '19: -34M Q3 '19: -36.4M Q4 '19: -36.1M Q1 '20: -32.7M Q2 '20: -32.3M Q3 '20: -28.1M Q4 '20: -29.8M Q1 '21: -32.9M Q2 '21: -40.7M Q3 '21: -47.5M Q4 '21: -54.6M Q1 '22: -64.1M Q2 '22: -67.5M Q3 '22: -76.3M Q4 '22: -93.8M Q1 '23: -134.8M Q2 '23: -161.9M Q3 '23: -180.2M Q4 '23: -184.2M Q1 '24: -167.4M Q2 '24: -168.3M Q3 '24: -197M Q4 '24: -232.3M Q1 '25: -279.7M Q2 '25: -309.1M Q3 '25: -326M Q4 '25: -276.4M Q1 '26: -303.4M Q2 '26: -333.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q3 '16: -13M Q4 '16: -15M Q1 '17: -19M Q2 '17: -21.6M Q3 '17: -24.4M Q4 '17: -28.4M Q1 '18: -27.6M Q2 '18: -25.1M Q3 '18: -26.3M Q4 '18: -27.3M Q1 '19: -31.7M Q2 '19: -34.3M Q3 '19: -36.6M Q4 '19: -36.1M Q1 '20: -32.8M Q2 '20: -32.3M Q3 '20: -28.2M Q4 '20: -29.8M Q1 '21: -32.9M Q2 '21: -40.8M Q3 '21: -47.7M Q4 '21: -54.9M Q1 '22: -64.6M Q2 '22: -68.3M Q3 '22: -77M Q4 '22: -94.6M Q1 '23: -135.5M Q2 '23: -162.7M Q3 '23: -181.3M Q4 '23: -185.1M Q1 '24: -168.2M Q2 '24: -168.8M Q3 '24: -197.4M Q4 '24: -232.8M Q1 '25: -280.3M Q2 '25: -309.6M Q3 '25: -326.3M Q4 '25: -276.9M Q1 '26: -303.8M Q2 '26: -335M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '20: 3.5M Q3 '20: 3.7M Q1 '21: 6.3M Q2 '21: 8.1M Q3 '21: 11.2M Q1 '22: 26.1M Q2 '22: 27.8M Q3 '22: 33.7M Q1 '23: 42.2M Q2 '23: 43.3M Q3 '23: 43.7M Q1 '24: 61.1M Q2 '24: 63.9M Q3 '24: 66.4M Q1 '25: 81.3M Q2 '25: 81.6M Q3 '20 Q2 '21 Q1 '22 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q4 '14: -3.50 Q1 '15: -0.42 Q2 '15: 3.98 Q3 '15: 3.99 Q4 '15: -21.04 Q1 '16: -26.17 Q2 '16: -31.72 Q3 '16: -38.25 Q4 '16: -27.58 Q1 '17: -22.60 Q2 '17: -17.06 Q3 '17: -10.41 Q4 '17: -1.50 Q1 '18: -1.08 Q2 '18: -1.03 Q3 '18: -1.05 Q4 '18: -1.09 Q1 '19: -1.29 Q2 '19: -1.29 Q3 '19: -1.36 Q4 '19: -1.34 Q1 '20: -3.61 Q2 '20: -5.14 Q3 '20: -6.26 Q4 '20: -31.26 Q1 '21: -31.52 Q2 '21: -31.91 Q3 '21: -31.68 Q4 '21: -7.08 Q1 '22: -5.15 Q2 '22: -4.00 Q3 '22: -3.61 Q4 '22: -4.07 Q1 '23: -4.70 Q2 '23: -4.91 Q3 '23: -5.14 Q4 '23: -5.31 Q1 '24: -4.49 Q2 '24: -4.24 Q3 '24: -4.30 Q4 '15 Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '23 Q3 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.